 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682022 |
| Pregnancy category |
|
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 3–9 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.001.514 |
| Chemical and physical data | |
| Formula | C11H12N2O2 |
| Molar mass | 204.229 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ethotoin (previously marketed asPeganone) is ananticonvulsant drug used in the treatment ofepilepsy.[1] It is ahydantoin, similar tophenytoin. It is not available in the United States.
Themechanism of action of ethotoin is similar to that of phenytoin.[citation needed]
Ethotoin is indicated for tonic-clonic and partial complex seizures.[2]
Ethotoin is available in 250 mg tablets.[3][4] It is taken orally in 4 to 6 divided doses per day, preferably after food.
Side effects includeataxia, visual disturbances, rash, andgastrointestinal problems.[citation needed]
Ethotoin is synthesized by the reaction of benzaldehyde oxynitrile (2) withurea orammonium bicarbonate, which forms an intermediate urea derivative (3) which on acidic conditions cyclizes to 5-phenylhydantoin (4).[5] Alkylation of this product usingethyl iodide leads to the formationof ethotoin (5).
